Exploring SYNC-T in Prostate Cancer

Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.

Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.

Brian Myre, MD, discusses early data with SYNC-T SV-102 in advanced/metastatic castration-resistant prostate cancer.